NICE | September 2018 | NICE approves new treatment for high-risk skin cancer
Dabrafenib with trametinib is recommended, within its marketing authorisation, as an option for the adjuvant treatment of resected stage III BRAF V600 mutation-positive melanoma in adults.
There are currently no adjuvant treatments available for stage III BRAF
V600 mutation-positive melanoma and there is a substantial risk of the
cancer returning and becoming incurable. Dabrafenib with trametinib is a
new adjuvant treatment aimed at curing the cancer by reducing the
likelihood that it will spread. It is therefore an important development in
managing stage III melanoma. (Source: NICE)
Make Sense Campaign | Head and neck cancer can leave anyone feeling unrecognisable
This week 17 – 21 September 2018 is European Head & Neck Cancer Week. The Make Sense Campaign is raising awareness of Head & Neck Cancer across Europe, led by the European Head and Neck Society (EHNS).
Cancer Research UK has published a newsletter focusing on smoking cessation aimed at community pharmacy teams.
The latest edition provides information on the safety of e-cigarettes, the power of very brief advice and the most successful ways to quit smoking. The magazine also doubles up as a poster to provide different options for quitting smoking.
Cancer Research UK also has a number of practical resources for health professionals on smoking cessation which pharmacy teams may find useful, especially if teams are planning to participate in Public Health England’s 28-day stop smoking campaign, Stoptober, which launches on 20 September.
Bloodwise | September 2018 |Over half of Brits don’t know symptoms of blood cancer
September is Blood Cancer Awareness Month and to raise awareness of blood cancers Bloodwise commissioned a survey to assess the general population’s understanding and knowledge of these types of cancer. Despite blood cancer being one of the most commonly diagnosed cancers, Bloodwise’s poll of 1000 adults found that only a tenth of the public were able to recognise its symptoms. Less than 1 % of people are “very confident” they could identify common symptoms of blood cancer, with over 50 per cent of the population not knowing any symptoms at all.
Blood cancer symptoms can be varied and often very vague. People can have just one or many of these before diagnosis – and in some cases, none at all:
Persistent and unexplained tiredness
Unexplained weight loss
Unexplained bruising and/or bleeding
Drenching night sweats
Lumps or swellings in the neck, head, groin or stomach
NHS England | August 2018 |Breast cancer survivors control their follow-up care in Maidstone
A new case study from NHS England highlights how patients with breast cancer in are able to control their own care in Maidstone, Kent. The Open Access programme enables patients to have access to regular mammograms, support advice and appropriate clinical follow up up to five years following treatment for breast cancer. The programme recognises patients as individuals and that the way in which they want to be supported may change during their recovery, the team introduced an Open Access Programme, based upon a successful model in place at the Royal Marsden Hospital.
A reduction of 3,000 breast outpatient appointments
Patients access suitable clinical appointments and contact their nurse appropriately.
Timely referral to an appropriate clinician (ie surgeon, oncologist, nurse)
Appointments aligned to patient need or want
Fast access to the Cancer Nurse to answer questions and concerns.
ICR | August 2018 | Drug combination gives ‘exciting’ results in ovarian and lung cancer in early trial
The results of an early clinical trial suggest that a combination of chemotherapy and a new drug could be used to provide treatment for patients with advanced ovarian and lung cancer, where other treatments had failed.
Scientists from The Institute of Cancer Research, London (ICR), and The Royal Marsden NHS Foundation Trust, decided to test vistusertib, which inhibits the activation of a specific molecule in ovarian cancer cells, to determine if the drug combination was safe for patients, the dosage and its efficacy. The combination of targeted drug vistusertib along with paclitaxel chemotherapy caused tumours of over 50 per cent of patients with ovarian cancer and over 33 % with lung cancer to shrink, and stopped patients’ cancers from growing for almost six months.
This far exceeds what is expected with standard treatments in patients with advanced disease who have already had, and have now become resistant to, standard treatment (Source: ICR).
NHS England |August 2018 |NHS70: spotlight on cancer
More people are surviving cancer than ever before. As we continue to celebrate 70 years of the NHS, we shine the spotlight on some of the key milestones that improved cancer diagnosis, treatment and care over the decades, as well as looking to the future on NHS cancer care.
NHS England will also explore some of the work of the National Cancer Programme, as the NHS implements an ambitious. They have produced a timeline of cancer care improvements in cancer prevention, treatment and care (Source: NHS England).
You can watch the video here:
The NHS has played a major role in advancing cancer treatment and care locally, nationally and globally. In this video, we acknowledge some of the key milestones that marked huge improvements in cancer prevention, treatment and care.